Skip to Content
Humans and technology

The FDA Has Approved Smart Pills That Track When Patients Take Their Meds

November 14, 2017

Hope you’re comfortable swallowing your tech, because America’s first digital pill is here. The drug, called Abilify MyCite, is an antipsychotic that can be used to treat schizophrenia and some cases of bipolar disorder. But unlike regular tablets, the pills contain a small ingestible sensor to record when they’re taken.

When ingested, the sensor registers against a smart patch worn by the patient, and it transmits data to a phone. In turn—if the patient chooses—that information can be shared with medics, caregivers, or family members.

That could be particularly useful for elderly people with faltering memories, for example, to track whether they are taking their drugs. Indeed, it’s hoped that the technology will reduce the bill caused by non-adherence to prescriptions, which for the U.S. has been estimated at up to $100 billion per year.

It’s a seminal moment for digital medicine: we’ve written about such pills for at least a decade, so their approval has been a long time coming. Still, not everyone’s happy about the news. Speaking to the New York Times, psychiatrist Peter Kramer warned of privacy concerns, calling digital drugs “a potentially coercive tool.”

Deep Dive

Humans and technology

Unlocking the power of sustainability

A comprehensive sustainability effort embraces technology, shifting from risk reduction to innovation opportunity.

Building a more reliable supply chain

Rapidly advancing technologies are building the modern supply chain, making transparent, collaborative, and data-driven systems a reality.

Building a data-driven health-care ecosystem

Harnessing data to improve the equity, affordability, and quality of the health care system.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.